Published 4 days ago • loading... • Updated 4 days ago

Junshi Biosciences Announces Toripalimab's Approval in Singapore

Summary by Benzinga

SHANGHAI, March 26, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the New Drug Application (the "NDA") for toripalimab (Singapore trade name: LOQTORZI®) in combination with cisplatin and gemcitabine for the first-line treatment of adu…

12 Articles

All

Left

Center

Right

The Hamilton Spectator

+8 Reposted by 8 other sources

Lean Left

Junshi Biosciences Announces Toripalimab’s Approval in Singapore

4 days ago·Hamilton, Canada

Read Full Article

Benzinga

Reposted by

Financial Post

Center

Junshi Biosciences Announces Toripalimab's Approval in Singapore

4 days ago·New York, United States

Read Full Article

ADKhabar

Junshi Biosciences Announces Toripalimabs Approval in Singapore

SHANGHAI, March 26, 2025 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the New Drug Application (the “NDA”) for toripalimab (Singapore trade name: LOQTORZI®) in combination with cisplatin and gemcitabine for the […]

4 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year